Delta-Fly Pharma, Inc. engages in the manufacturing, sale, research and development of pharmaceutical products for cancer treatment. It also provides module technology for motorcars, telepone, oncology drug discovery, treating metastatic ovarian cancer with DFP-10825, liposome-conjugated RNAi molecule and others. The company was founded by Kiyoshi Eshima on December 6, 2010 and is headquartered in Tokushima, Japan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company